NCT04513002View on ClinicalTrials.gov

Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

March 17, 2023

Study Completion Date

July 10, 2023

Conditions
Ataxia Telangiectasia
Interventions
DIETARY_SUPPLEMENT

Triheptanoin

Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.

Trial Locations (1)

4001

Queensland Children's Hospital, Brisbane

All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

lead

The University of Queensland

OTHER